Sign in
Taking people in United StatesNo phase

Studying biomarkers in people with lung, head and neck, or airway cancers

Studies sputum and tissue samples to look for biomarkers linked to cancer in adults.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Status
Recruiting
People taking part
700 people, planned
Started
3 May 2001
Expected to end
30 Oct 2028
Type of study
Observational
Treatments tested
  • immunohistochemistry staining method
  • laboratory biomarker analysis
  • sputum cytology
  • biopsy
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with moderate or severe dysplasia of the airway lining, or with lung, head and neck, or aerodigestive cancer, plus people without dysplasia who need a bronchoscopy for other reasons.

Age
21 to 90 years
Sex
Men and women
Disease stage
Moderate or severe dysplasia of the respiratory lining, or lung, head and neck, or aerodigestive tract cancer, including fully resected Stage I non-small cell lung cancer. A group without dysplasia is also included.
Earlier treatment
Some people have had a bronchogenic carcinoma resected or lived one year or more after an aerodigestive cancer. Others have had previous high-grade dysplasia or worse and need a repeat bronchoscopy to monitor treatment response.

Main reasons for not taking part

  • Clear signs of a bleeding disorder
  • Life-threatening heart rhythm problem
  • Oxygen saturation under 90% with extra oxygen before bronchoscopy
  • Active coronary artery disease, including a heart attack within 6 weeks, or poorly controlled heart failure
  • Acute bronchitis or pneumonia within 8 weeks

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Two broad patient groups are of interest: those with extensive and severe dysplasia of the respiratory epithelium and those without dysplasia of the respiratory epithelium. The patients with dysplasia will be recruited from the following:
  • Individuals identified through the SPORE Tissue Procurement Screening Project with moderate or severe dysplasia
  • Patients identified by private and academic physicians with moderate or severe dysplasia on cytology
  • One year or greater survivors of one or more aerodigestive system carcinomas
  • Patients with head and neck cancers who are undergoing routine panendoscopy
  • Patients undergoing resection of a bronchogenic carcinoma
  • Fully resected Stage I non-small cell cancer patients
  • Patient's undergoing bronchoscopy for diagnosis or staging of suspected lung cancer
  • Subjects with previous high-grade dysplasia or worse undergoing subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment
  • Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes
  • Patients without dysplasia will be: patients undergoing clinically indicated bronchoscopy for conditions other than suspected lung cancer

Who cannot take part

  • Hypoxemia (less than 90% saturation with supplemental oxygen) prior to bronchoscopy
  • Patients are not eligible if any one of the following conditions exist:
  • Clinically apparent bleeding diathesis
  • Cardiac dysrhythmia that is potentially life threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (< 2/minute) premature ventricular contractions are not exclusionary
  • Evidence of clinically active coronary artery disease, including myocardial infarction within 6 weeks, anginal chest pain, or poorly controlled congestive heart failure, or any other serious medical condition which would preclude a patient from undergoing a bronchoscopy
  • Acute bronchitis or pneumonia within 8 weeks, except if these are considered clinically to be possibly a result of lung cancer
  • Inability to give informed consent

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 90 years old?

Where in United States

  • University of Colorado Cancer Center at UC Health Sciences CenterAurora, United StatesContact: Clinical Trials Office - University of Colorado Cancer CenterTaking people

About the trial

What the trial wants to find out

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.

Read full original descriptionShow less

PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Treatments tested

  • immunohistochemistry staining method
  • laboratory biomarker analysis
  • sputum cytology
  • biopsy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarkers and Dysplastic Respiratory Epithelium
Plain-language title
Studying biomarkers in people with lung, head and neck, or airway cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT00900419, who can take part
Record updated
3 November 2026